Eli Lilly (LLY) continues to hold the market's attention with its consistent stock performance and strategic moves. It recently made waves with its announcement of acquiring Ventyx Biosciences and earning Breakthrough Therapy designation from the FDA for its ovarian cancer treatment sofetabart mipitecan. Despite the impressive 36% year-on-year surge and 190% increase in the last three years, analysts question its ability to maintain this momentum. Notably, Bernstein predicts LLY to hit $1,300 per share while Guggenheim reduces its price target to $1,161 — both maintaining a 'Buy' rating. LLY's focus on volume over price underlines the 2026 resolution. Their collaboration with NVIDIA for an AI lab cements its leadership in obesity treatment. Meanwhile, the company denied acquisition talks with Abivax amid swirling rumors and continued its rivalry with Novo Nordisk in the obesity-pill market. There's a mix of buying and selling activity around LLY stock, with Symphony and Deseret reducing their stakes while Dash Acquisitions, Edge Financial Advisors, and Jennison Associates increase theirs. Several financial advisors maintain their faith in LLY's long-term investment value.
Eli Lilly LLY News Analytics from Thu, 30 Oct 2025 07:00:00 GMT to Sat, 24 Jan 2026 16:17:43 GMT -
Rating 7
- Innovation 4
- Rumor -3
